Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02135 瑞麗醫美國際控股
Raily Aesthetic Medicine International Holdings
Listing Date2020/12/28
Listing Price0.400
  • 0.305 +0.005 (+1.667%)    Sink Below Listing Price
  • 15-min delayed, last update: 02/12/2021 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    400 lot
  • One Lot Success Rate

Raily Aesthetic Medicine International Holdings is a leading aesthetic medical service provider in Zhejiang Province, the PRC. It offers a broad range of aesthetic medical services to our clients to meet their different aesthetic and anti-aging objectives. Its aesthetic medical services principally include aesthetic surgery services, comprising aesthetic surgical procedures performed on various parts of the face or body; minimally-invasive aesthetic services, primarily comprising aesthetic injection procedures; and aesthetic dermatology services, primarily comprising various aesthetic energy-based procedures.

The Group has grown its network since its operation commenced in August 2008. It owned and operated a network of four private for-profit aesthetic medical institutions in the PRC, while three of them were located in Zhejiang Province and one of them was located in Anhui Province. All of aesthetic medical institutions are operated under its registered trademark "Raily".

According to the Frost & Sullivan Report, the Group had a market share of approximately 4.1% and 1.9%, and ranked fourth and fifth, in terms of aesthetic medical service revenue in 2019 among all private aesthetic medical service providers in Hangzhou City and Zhejiang Province, respectively.

For the two years ended 31 December 2018, aesthetic surgery services segment was its largest single source of revenue. The revenue from minimally-invasive aesthetic services and aesthetic dermatology services increased significantly. As at 30 June 2020, the Group had 64 physicians who practiced at its aesthetic medical institutions with an average industry experience of approximately 12 years.

MarketHong Kong (Main Board)
Business NatureHealth Care
Board Lot10,000
Registrar & Transfer OfficeTricor Investor Services
No. of Offer Shares343m shares
No. of International Placing Shares308m shares
No. of HK Offer Shares34.25m shares
Offer Price$0.30 - $0.40
Nominal ValueUS$ 0.01 each
Stock Code2135
Sole SponsorInnovax Capital
Joint Global CoordinatorsInnovax Securities, Elstone Securities
Joint BookrunnersInnovax Securities, Elstone Securities, BOCOM International Securities, Essence International Securities (Hong Kong), First Fidelity Capital (International)
Joint Lead ManagersInnovax Securities, Elstone Securities, BOCOM International Securities, Essence International Securities (Hong Kong), First Fidelity Capital (International), Kirin Securities, Kingkey Securities Group, Realord Asia Pacific Securities, Sun International Securities
Application PeriodDec 15 (Tue) - Noon, Dec 18 (Fri)
Price Determination DateOn or Before 5pm, Dec 18 (Fri)
Result Announcement DateOn or Before Dec 24 (Thu)
Dispatch of Shares and Refund ChequesOn or Before Dec 24 (Thu)
Dealings in Shares commence onDec 28, 2020. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveFu Haishu (Chairman), Yu Kai, Song Jianliang
Non-ExecutiveXie Lijun, Fan Qirui
Independent Non-ExecutiveCao Dequan, Yang Xiaofen, Liu Teng
Director Fu Haishu53.98%
Beauty Milkway6.28%
Shanghai Donghua5.46%
Huamei Medical5.46%
(Year ended Dec 31)
2020 *20192018
Gross Profit24,286101,03892,493
Pre-Taxed Profit(12,352)16,38826,383
Attributable Profit for the period(12,000)9,89717,855
* For the six months ended June 30, 2020.
Offer Price$0.30 - $0.40
Capitalization$617m - $822m
Unaudited pro forma adj NAV / share$0.07 - $0.08
Assuming the offer price being at the mid-point of $0.35, the net proceeds raised would be HK$56.0m, of which:
* $15.7m (28.0%) to be used for renovating all existing aesthetic medical institutions and expand capacity;
* $15.7m (28.0%) to be used for funding the capital expenditure and initial operating costs for establishing our new aesthetic medical institution in Shanghai City;
* $8.4m (15.0%) to be used for potential strategic acquisition of aesthetic medical institutions in Zhejiang Province in the PRC;
* $6.1m (11.0%) to be used for the purchase of aesthetic medical service equipment and medical consumables ;
* $4.5m (8.0%) to be used for active promotion of our brand; and
* the balance of $5.6m (10.0%) as additional working capital.
Code Name Nominal Change %Change
02135RAILY AESMEDup0.3050.0051.667%
15-min delayed, last updated: 02/12/2021 17:59
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.